Bevantolol: Uses, Side Effects & Dosage Guide

Bevantolol, also known by its international nonproprietary name (INN), is a drug candidate that belongs to the class of beta-blockers and calcium channel blockers. It has been extensively studied for its potential use in the treatment of angina pectoris and hypertension.

1. Introduction to Bevantolol

Bevantolol is a new beta-adrenoceptor antagonist that possesses a high degree of selectivity for beta-1 adrenoceptors. It is devoid of intrinsic sympathomimetic activity and has weak membrane-stabilizing and local anesthetic properties. DrugBank provides an overview of bevantolol, describing it as a cardioselective β-adrenoreceptor antagonist with β sympathomimetic activity, weak membrane-stabilizing, and local anesthetic properties.

2. Chemical Composition

The chemical formula of bevantolol is C20H27NO4, and its molecular weight is 345.43 g/mol. It is a selective β1-blocker that is structurally related to pindolol and bucindolol. Rouot et al. (1986) described the synthesis and characterization of bevantolol, highlighting its unique chemical structure and properties.

3. Mechanism of Action

Bevantolol acts as a beta-1 adrenoceptor antagonist, meaning it selectively blocks the action of beta-1 adrenergic receptors. This mechanism is responsible for its effects in reducing blood pressure and heart rate, as well as its antianginal properties. Buckingham et al. (1989) studied the pharmacodynamics and pharmacokinetics of bevantolol, shedding light on its unique mechanism of action and receptor binding properties.

4. Medical Uses

The primary medical uses of bevantolol include the treatment of angina pectoris and the management of hypertension. Its beta-blocking and calcium channel blocking properties make it an attractive therapeutic option for these cardiovascular conditions. Levine et al. (1989) conducted clinical trials evaluating the efficacy of bevantolol in the treatment of angina pectoris, demonstrating its potential as an effective antianginal agent.

5. Drug Interactions

Like other beta-blockers, bevantolol may interact with various cardiovascular drugs, such as diuretics, ACE inhibitors, and calcium channel blockers. Caution should be exercised when co-administering bevantolol with non-cardiovascular drugs that may affect its metabolism or potentiate its effects. Giudicelli et al. (1989) investigated the potential drug interactions of bevantolol, providing valuable insights for safe and effective co-administration.

6. Side Effects and Contraindications

Common side effects associated with bevantolol include fatigue, dizziness, bradycardia, and hypotension. Severe adverse reactions, though rare, may include bronchospasm, heart failure, and allergic reactions. Bevantolol is contraindicated in patients with certain heart conditions, such as severe bradycardia or heart block. Levine et al. (1989) also reported on the safety profile and tolerability of bevantolol based on their clinical trial findings.

7. Clinical Trials and Research

Several clinical trials have been conducted to evaluate the efficacy, safety, and pharmacokinetics of bevantolol in various patient populations. Preclinical studies have also investigated its pharmacological properties and potential therapeutic applications. Levine et al. (1989) and Buckingham et al. (1989) are examples of notable research studies on bevantolol, contributing to our understanding of its clinical profile.

8. Comparative Studies

Comparative studies have been conducted to evaluate the efficacy and safety of bevantolol relative to other beta-blockers, such as metoprolol and atenolol, as well as calcium channel blockers. These studies help to establish the relative advantages and disadvantages of bevantolol in various clinical settings. Giudicelli et al. (1989) compared the pharmacokinetic profiles of bevantolol and atenolol, providing insights into their respective therapeutic potentials.

9. Pharmacological Profile

Bevantolol exhibits cardioselectivity, meaning it has a higher affinity for beta-1 adrenoceptors in the heart compared to beta-2 adrenoceptors in other tissues. It lacks significant sympathomimetic activity and has weak membrane-stabilizing and local anesthetic properties. DrugBank provides a comprehensive overview of bevantolol’s pharmacological profile, including its receptor binding affinities and pharmacodynamic properties.

10. Bevantolol Hydrochloride

Bevantolol hydrochloride is the salt form of the drug, which is commonly used for pharmaceutical formulations. This form enhances the solubility and bioavailability of bevantolol, allowing for effective oral administration and absorption. Levine et al. (1989) conducted clinical trials using the bevantolol hydrochloride formulation, demonstrating its potential as a therapeutic agent.

11. Regulatory Status

The regulatory approval status of bevantolol varies across different regions and countries. While it has been approved for medical use in some countries, its development and commercialization have been discontinued in others. Factors such as clinical trial results, safety profiles, and market considerations have influenced the regulatory decisions regarding bevantolol.

12. Synthesis and Production

The synthesis and production of bevantolol involve several steps, including chemical reactions and purification processes. Industrial-scale manufacturing techniques are employed to ensure consistent quality and purity of the drug substance. Rouot et al. (1986) provided insights into the synthesis and characterization of bevantolol, contributing to our understanding of its production processes.

13. Future Directions

While bevantolol has been extensively studied, there is ongoing research exploring its potential future applications and investigating its pharmacological properties in various disease models. Additionally, researchers continue to explore novel drug delivery systems and formulations to enhance the therapeutic potential of bevantolol.

14. Historical Context

Bevantolol was developed as a drug candidate in the late 20th century, with the aim of providing a more selective and effective treatment option for cardiovascular conditions. Its development timeline and notable milestones, including clinical trials and regulatory approvals, have been documented in various scientific publications and literature.

15. Miscellaneous Studies

Apart from clinical trials and comparative studies, researchers have conducted experimental studies on animal models to evaluate the effects of bevantolol on various tissues and organ systems. These studies have provided valuable insights into the pharmacological properties and potential applications of bevantolol in different therapeutic areas.